Company: INTS
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001567264-25-000010
Chunk: 12

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 16
Chunk 12
---
,851- 10,000 - 10,000  Conversion of convertible notes into common stock -- -- -- 1,399,716- 6,998 - 6,998  Issuance of warrants to convertible note holders -- -- -- -- 159 - 159  Exercise of options -- -- -- 25,000- 50 - 50  Deemed dividend -- -- -- 264,707- 1,324 (1,324)-  Stock-based compensation expense -- -- -- -- 1,398 - 1,398  Net loss -- -- -- -- (10,538)(10,538)Balances at December 31, 2023-$- -$- -$- 13,709,377$1 $63,676 $(50,515)$13,162  Issuance of common stock in registered direct offering, net of $321 issuance costs -- -- -- 1,237,1131 1,360 - 1,361  Issuance of warrants in registered direct offering, net of $252 issuance costs -- -- -- -- 1,068 - 1,068  Issuance of common stock in ATM offering, net of $82 issuance costs -- -- -- 51,820- 150 - 150  Issuance of common stock in exchange for services -- -- -- 11,750- 51 - 51  Exercise of options -- -- -- 88,500- 266 - 266  Exercise of warrants -- -- -- 24,313- 55 - 55  Stock-based compensation expense -- -- -- -- 3,073 - 3,073  Net loss -- -- -- -- - (16,268)(16,268)Balances at December 31, 2024-$- -$- -$- 15,122,873$2 $69,699 $(66,783)$2,918 

The accompanying notes are an integral part of these financial statements.

F-5

INTENSITY THERAPEUTICS, INC.

STATEMENTS OF CASH FLOWS

(in thousands)

Years Ended December 31,202420